Balyasny Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Balyasny Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.2M	Buy	464,600 +382,600	+467%	+$22.3M	0.04%	551
2025 Q4	$4.42M	Buy	82,000 +38,900	+90%	+$1.87M	0.01%	1461
2025 Q3	$1.94M	Sell	43,100 -27,300	-39%	-$1.27M	﹤0.01%	1808
2025 Q2	$3.26M	Sell	70,400 -94,800	-57%	-$4.65M	﹤0.01%	1499
2025 Q1	$10.1M	Buy	165,200 +101,100	+158%	+$5.89M	0.02%	905
2024 Q4	$3.63M	Buy	64,100 +11,400	+22%	+$637K	0.01%	1422
2024 Q3	$2.73M	Buy	+52,700	New	+$2.47M	﹤0.01%	1547
2024 Q2	–	Sell	-26,400	Closed	-$1.43M	–	2603
2024 Q1	$1.43M	Sell	26,400 -7,000	-21%	-$357K	﹤0.01%	1657
2023 Q4	$1.71M	Buy	33,400 +10,100	+43%	+$530K	﹤0.01%	1501
2023 Q3	$1.35M	Sell	23,300 -16,700	-42%	-$1.02M	﹤0.01%	1489
2023 Q2	$2.56M	Hold	40,000	–	–	0.01%	1296
2023 Q1	$2.77M	Sell	40,000 -128,400	-76%	-$9.06M	0.01%	1332
2022 Q4	$12.1M	Sell	168,400 -330,000	-66%	-$24.9M	0.03%	660
2022 Q3	$35.4M	Sell	498,400 -287,300	-37%	-$20.8M	0.11%	237
2022 Q2	$60.5M	Buy	785,700 +10,700	+1%	+$815K	0.2%	111
2022 Q1	$56.6M	Buy	+775,000	New	+$52M	0.18%	113
2021 Q3	–	Sell	-12,800	Closed	-$855K	–	1959
2021 Q2	$855K	Buy	+12,800	New	+$835K	﹤0.01%	1359
2020 Q4	–	Sell	-300,000	Closed	-$18.1M	–	1341
2020 Q3	$18.1M	Buy	300,000 +100,000	+50%	+$6.02M	0.13%	215
2020 Q2	$11.8M	Buy	+200,000	New	+$12M	0.1%	301
2018 Q1	–	Sell	-1,022,500	Closed	-$62.7M	–	1953
2017 Q4	$62.7M	Buy	1,022,500 +622,500	+156%	+$38.9M	0.2%	130
2017 Q3	$25.5M	Buy	+400,000	New	+$23.4M	0.1%	274
2015 Q1	–	Sell	-46,500	Closed	-$2.75M	–	947
2014 Q4	$2.75M	Buy	+46,500	New	+$2.62M	0.03%	523

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's BMY Position: Q1 2026 in Review

Balyasny Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 91% in Q1 2026, selling an estimated $71.3M and leaving 118,697 shares worth $7.2M. The position accounts for 0.01% of the portfolio, ranked #1187.

Balyasny Asset Management first reported a position in BMY in Q1 2015 and has held it in 39 quarters since. The position peaked at $100M in Q4 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Balyasny Asset Management held 118,697 shares of Bristol-Myers Squibb worth $7.2M as of Q1 2026.
Balyasny Asset Management sold 1,222,647 Bristol-Myers Squibb shares in Q1 2026, an estimated $71.3M.
Bristol-Myers Squibb made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1187 holding.
Balyasny Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 39 quarters since.
Balyasny Asset Management's Bristol-Myers Squibb position peaked at $100M in Q4 2016.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.